Kohner EM, Patel V, Rassam SMB. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes. 1995;44:603–7. https://doi.org/10.2337/diab.44.6.603.
Roy S, Ha J, Trudeau K, Beglova E. Vascular basement membrane thickening in diabetic retinopathy. Curr Eye Res. 2010;35:1045–56. https://doi.org/10.3109/02713683.2010.514659.
Roy S, Kim D. Retinal capillary basement membrane thickening: role in the pathogenesis of diabetic retinopathy. Prog Retin Eye Res. 2021;82: 100903. https://doi.org/10.1016/j.preteyeres.2020.100903.
Shen J, San W, Zheng Y, et al. Different types of cell death in diabetic endothelial dysfunction. Biomed Pharmacother. 2023;168: 115802. https://doi.org/10.1016/j.biopha.2023.115802.
Li W, Yanoff M, Liu X, Ye X. Retinal capillary pericyte apoptosis in early human diabetic retinopathy. Chin Med J. 1997;110:659–63.
Enge M. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J. 2002;21:4307–16. https://doi.org/10.1093/emboj/cdf418.
Perais J, Agarwal R, Evans JR, et al. Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy. Cochrane Database Syst Rev. 2023. https://doi.org/10.1002/14651858.CD013775.pub2.
Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366:1227–39. https://doi.org/10.1056/NEJMra1005073.
Torres-Costa S, Alves Valente MC, Falcão-Reis F, Falcão M. Cytokines and growth factors as predictors of response to medical treatment in diabetic macular edema. J Pharmacol Exp Ther. 2020;373:445–52. https://doi.org/10.1124/jpet.119.262956.
Chan-Ling T, Koina ME, McColm JR, et al. Role of CD44+ stem cells in mural cell formation in the human choroid: evidence of vascular instability due to limited pericyte ensheathment. Invest Ophthalmol Vis Sci. 2011;52:399–410. https://doi.org/10.1167/iovs.10-5403.
Rudraraju M, Narayanan SP, Somanath PR. Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy. Pharmacol Res. 2020;161: 105115. https://doi.org/10.1016/j.phrs.2020.105115.
Klaassen I, Van Noorden CJF, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013;34:19–48. https://doi.org/10.1016/j.preteyeres.2013.02.001.
O’Leary F, Campbell M. The blood–retina barrier in health and disease. FEBS J. 2023;290:878–91. https://doi.org/10.1111/febs.16330.
Bora K, Kushwah N, Maurya M, et al. Assessment of inner blood-retinal barrier: animal models and methods. Cells. 2023;12:2443. https://doi.org/10.3390/cells12202443.
Zihni C, Mills C, Matter K, Balda MS. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol. 2016;17:564–80. https://doi.org/10.1038/nrm.2016.80.
Díaz-Coránguez M, Ramos C, Antonetti DA. The inner blood-retinal barrier: cellular basis and development. Vision Res. 2017;139:123–37. https://doi.org/10.1016/j.visres.2017.05.009.
Sorrentino FS, Allkabes M, Salsini G, et al. The importance of glial cells in the homeostasis of the retinal microenvironment and their pivotal role in the course of diabetic retinopathy. Life Sci. 2016;162:54–9. https://doi.org/10.1016/j.lfs.2016.08.001.
Daruich A, Matet A, Moulin A, et al. Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res. 2018;63:20–68. https://doi.org/10.1016/j.preteyeres.2017.10.006.
Kur J, Newman EA, Chan-Ling T. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Prog Retin Eye Res. 2012;31:377–406. https://doi.org/10.1016/j.preteyeres.2012.04.004.
Karlstetter M, Scholz R, Rutar M, et al. Retinal microglia: just bystander or target for therapy? Prog Retin Eye Res. 2015;45:30–57. https://doi.org/10.1016/j.preteyeres.2014.11.004.
Laties AM. Central retinal artery innervation. Absence of adrenergic innervation to the intraocular branches. Arch Ophthalmol Chic Ill. 1967;77:405–9. https://doi.org/10.1001/archopht.1967.00980020407021.
Németh J, Knézy K, Tapasztó B, et al. Different autoregulation response to dynamic exercise in ophthalmic and central retinal arteries: a color doppler study in healthy subjects. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2002;240:835–40. https://doi.org/10.1007/s00417-002-0552-1.
Riva CE, Logean E, Falsini B. Visually evoked hemodynamical response and assessment of neurovascular coupling in the optic nerve and retina. Prog Retin Eye Res. 2005;24:183–215. https://doi.org/10.1016/j.preteyeres.2004.07.002.
Newman EA. Functional hyperemia and mechanisms of neurovascular coupling in the retinal vasculature. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2013;33:1685–95. https://doi.org/10.1038/jcbfm.2013.145.
Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflüg Arch Eur J Physiol. 2000;440:653–66. https://doi.org/10.1007/s004240000307.
Zeng Y, Adamson RH, Curry F-RE, Tarbell JM. Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Physiol-Heart Circ Physiol. 2014;306:H363–72. https://doi.org/10.1152/ajpheart.00687.2013.
Nieuwdorp M, Van Haeften TW, Gouverneur MCLG, et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes. 2006;55:480–6. https://doi.org/10.2337/diabetes.55.02.06.db05-1103.
Reitsma S, Slaaf DW, Vink H, et al. The endothelial glycocalyx: composition, functions, and visualization. Pflüg Arch Eur J Physiol. 2007;454:345–59. https://doi.org/10.1007/s00424-007-0212-8.
Harris NR, Leskova W, Kaur G, et al. Blood flow distribution and the endothelial surface layer in the diabetic retina. Biorheology. 2019;56:181–9. https://doi.org/10.3233/BIR-180200.
Curry FE, Adamson RH. Endothelial glycocalyx: permeability barrier and mechanosensor. Ann Biomed Eng. 2012;40:828–39. https://doi.org/10.1007/s10439-011-0429-8.
Becker BF, Chappell D, Jacob M. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol. 2010;105:687–701. https://doi.org/10.1007/s00395-010-0118-z.
Jacob M, Bruegger D, Rehm M, et al. The endothelial glycocalyx affords compatibility of starling’s principle and high cardiac interstitial albumin levels. Cardiovasc Res. 2007;73:575–86. https://doi.org/10.1016/j.cardiores.2006.11.021.
Pillinger NL, Kam PCA. Endothelial glycocalyx: basic science and clinical implications. Anaesth Intensiv Care. 2017;45:295–307. https://doi.org/10.1177/0310057X1704500305.
Lipowsky HH, Gao L, Lescanic A. Shedding of the endothelial glycocalyx in arterioles, capillaries, and venules and its effect on capillary hemodynamics during inflammation. Am J Physiol Heart Circ Physiol. 2011;301:H2235–45. https://doi.org/10.1152/ajpheart.00803.2011.
Dogné S, Flamion B, Caron N. Endothelial glycocalyx as a shield against diabetic vascular complications: involvement of hyaluronan and hyaluronidases. Arterioscler Thromb Vasc Biol. 2018;38:1427–39. https://doi.org/10.1161/ATVBAHA.118.310839.
Lieleg O, Baumgärtel RM, Bausch AR. Selective filtering of particles by the extracellular matrix: an electrostatic bandpass. Biophys J. 2009;97:1569–77. https://doi.org/10.1016/j.bpj.2009.07.009.
Rehm M, Zahler S, Lötsch M, et al. Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed. Anesthesiology. 2004;100:1211–23. https://doi.org/10.1097/00000542-200405000-00025.
Betteridge KB, Arkill KP, Neal CR, et al. Sialic acids regulate microvessel permeability, revealed by novel in vivo studies of endothelial glycocalyx structure and function. J Physiol. 2017;595:5015–35. https://doi.org/10.1113/JP274167.
Kaur G, Harris NR. Endothelial glycocalyx in retina, hyperglycemia, and diabetic retinopathy. Am J Physiol Cell Physiol. 2023;324:C1061–77. https://doi.org/10.1152/ajpcell.00188.2022.
Leskova W, Pickett H, Eshaq RS, et al. Effect of diabetes and hyaluronidase on the retinal endothelial glycocalyx in mice. Exp Eye Res. 2019;179:125–31. https://doi.org/10.1016/j.exer.2018.11.012.
Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010;53:2646–55. https://doi.org/10.1007/s00125-010-1910-x.
Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23:123–30. https://doi.org/10.1681/ASN.2011040378.
Machin DR, Sabouri M, Zheng X, Donato AJ. Therapeutic strategies targeting the endothelial glycocalyx. Curr Opin Clin Nutr Metab Care. 2023;26:543–50. https://doi.org/10.1097/MCO.0000000000000973.
Bhattacharjee PS, Huq TS, Potter V, et al. High-glucose-induced endothelial cell injury is inhibited by a peptide derived from human apolipoprotein E. PLoS ONE. 2012;7: e52152. https://doi.org/10.1371/journal.pone.0052152.
Kaur G, Song Y, Xia K, et al. Effect of high glucose on glycosaminoglycans in cultured retinal endothelial cells and rat retina. Glycobiology. 2022;32:720–34. https://doi.org/10.1093/glycob/cwac029.
Kumase F, Morizane Y, Mohri S, et al. Glycocalyx degradation in retinal and choroidal capillary endothelium in rats with diabetes and hypertension. Acta medica Okayama. 2010;64(5):277–83.
Shafat I, Ilan N, Zoabi S, et al. Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PLoS ONE. 2011;6: e17312. https://doi.org/10.1371/journal.pone.0017312.
Noda K, Ishida S, Inoue M, et al. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Investig Opthalmology Vis Sci. 2003;44:2163. https://doi.org/10.1167/iovs.02-0662.
Gui F, You Z, Fu S, et al. Endothelial dysfunction in diabetic retinopathy. Front Endocrinol. 2020;11:591. https://doi.org/10.3389/fendo.2020.00591.
Wisniewska-Kruk J, Klaassen I, Vogels IMC, et al. Molecular analysis of blood–retinal barrier loss in the akimba mouse, a model of advanced diabetic retinopathy. Exp Eye Res. 2014;122:123–31. https://doi.org/10.1016/j.exer.2014.03.005.
Yurchenco PD, Amenta PS, Patton BL. Basement membrane assembly, stability and activities observed through a developmental lens. Matrix Biol. 2004;22:521–38. https://doi.org/10.1016/j.matbio.2003.10.006.
Trost A, Lange S, Schroedl F, et al. Brain and retinal pericytes: origin, function and role. Front Cell Neurosci. 2016. https://doi.org/10.3389/fncel.2016.00020.
Morris AWJ, Sharp MM, Albargothy NJ, et al. Vascular basement membranes as pathways for the passage of fluid into and out of the brain. Acta Neuropathol. 2016;131:725–36. https://doi.org/10.1007/s00401-016-1555-z.
Hoddevik EH, Rao SB, Zahl S, et al. Organisation of extracellular matrix proteins laminin and agrin in pericapillary basal laminae in mouse brain. Brain Struct Funct. 2020;225:805–16. https://doi.org/10.1007/s00429-020-02036-3.
Jayadev R, Sherwood DR. Basement membranes. Curr Biol. 2017;27:R207–11. https://doi.org/10.1016/j.cub.2017.02.006.
Bianchi E, Ripandelli G, Taurone S, et al. Age and diabetes related changes of the retinal capillaries: an ultrastructural and immunohistochemical study. Int J Immunopathol Pharmacol. 2016;29:40–53. https://doi.org/10.1177/0394632015615592.
Hägg E. Glomerular basement membrane thickening in rats with long-term alloxan diabetes: a quantitative electron microscopic study. Acta Pathol Microbiol Scand. 1974;82A:211–9. https://doi.org/10.1111/j.1699-0463.1974.tb03845.x.
Siperstein MD, Unger RH, Madison LL. Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients. J Clin Invest. 1968;47:1973–99. https://doi.org/10.1172/JCI105886.
Friederici HHR, Randolph Tucker W, Schwartz TB. Observations on small blood vessels of skin in the normal and in diabetic patients. Diabetes. 1966;15:233–50. https://doi.org/10.2337/diab.15.4.233.
Toussaint D, Dustin P. Electron microscopy of normal and diabetic retinal capillaries. Arch Ophthalmol. 1963;70:96–108. https://doi.org/10.1001/archopht.1963.00960050098015.
Yang X, Scott HA, Monickaraj F, et al. Basement membrane stiffening promotes retinal endothelial activation associated with diabetes. FASEB J. 2016;30:601–11. https://doi.org/10.1096/fj.15-277962.
Sternberg M, Andre J, Peyroux J. Inhibition of the alpha-glucosidase specific for collagen disaccharide units in diabetic rat kidney by in vivo glucose levels: possible contribution to basement membrane thickening. Diabetologia. 1983. https://doi.org/10.1007/BF00282715.
Beyer TA, Hutson NJ. Introduction: evidence for the role of the polyol pathway in the pathophysiology of diabetic complications. Metabolism. 1986;35:1–3. https://doi.org/10.1016/0026-0495(86)90178-2.
Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405–12. https://doi.org/10.2337/diab.40.4.405.
Klaassen I, Van Geest RJ, Kuiper EJ, et al. The role of CTGF in diabetic retinopathy. Exp Eye Res. 2015;133:37–48. https://doi.org/10.1016/j.exer.2014.10.016.
Kugler EC, Greenwood J, MacDonald RB. The “neuro-glial-vascular” unit: the role of glia in neurovascular unit formation and dysfunction. Front Cell Dev Biol. 2021;9: 732820. https://doi.org/10.3389/fcell.2021.732820.
Li X, Qin W, Qin X, et al. Meta-analysis of the relationship between ocular and peripheral serum IL-17A and diabetic retinopathy. Front Endocrinol. 2024;15:1320632. https://doi.org/10.3389/fendo.2024.1320632.
Niu Y, Zhang W, Shi J, et al. The relationship between circulating growth differentiation factor 15 levels and diabetic retinopathy in patients with type 2 diabetes. Front Endocrinol. 2021;12: 627395. https://doi.org/10.3389/fendo.2021.627395.
Chen H, Zhang X, Liao N, et al. Decreased expression of glucagon-like peptide-1 receptor and Sodium-glucose co-transporter 2 in patients with proliferative diabetic retinopathy. Front Endocrinol. 2022;13:1020252. https://doi.org/10.3389/fendo.2022.1020252.
Niu T, Shi X, Liu X, et al. Porous Se@SiO2 nanospheres alleviate diabetic retinopathy by inhibiting excess lipid peroxidation and inflammation. Mol Med. 2024;30:24. https://doi.org/10.1186/s10020-024-00785-z.
Cong X, Kong W. Endothelial tight junctions and their regulatory signaling pathways in vascular homeostasis and disease. Cell Signal. 2020;66: 109485. https://doi.org/10.1016/j.cellsig.2019.109485.
Chiba H, Osanai M, Murata M, et al. Transmembrane proteins of tight junctions. Biochim Biophys Acta BBA Biomembr. 2008;1778:588–600. https://doi.org/10.1016/j.bbamem.2007.08.017.
Furuse M. Molecular basis of the core structure of tight junctions. Cold Spring Harb Perspect Biol. 2010;2: a002907. https://doi.org/10.1101/cshperspect.a002907.
Danesh-Meyer HV, Zhang J, Acosta ML, et al. Connexin43 in retinal injury and disease. Prog Retin Eye Res. 2016;51:41–68. https://doi.org/10.1016/j.preteyeres.2015.09.004.
Roy S, Kim D, Lim R. Cell-cell communication in diabetic retinopathy. Vision Res. 2017;139:115–22. https://doi.org/10.1016/j.visres.2017.04.014.
Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the β-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8:1223–34. https://doi.org/10.1038/ncb1486.
Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. J Biol Chem. 1999;274:23463–7. https://doi.org/10.1074/jbc.274.33.23463.
Gu X, Fliesler SJ, Zhao Y-Y, et al. Loss of caveolin-1 causes blood-retinal barrier breakdown, venous enlargement, and mural cell alteration. Am J Pathol. 2014;184:541–55. https://doi.org/10.1016/j.ajpath.2013.10.022.
Tien T, Barrette KF, Chronopoulos A, Roy S. Effects of high glucose-induced Cx43 downregulation on occludin and ZO-1 expression and tight junction barrier function in retinal endothelial cells. Investig Opthalmology Vis Sci. 2013;54:6518. https://doi.org/10.1167/iovs.13-11763.
Saker S, Stewart EA, Browning AC, et al. The effect of hyperglycaemia on permeability and the expression of junctional complex molecules in human retinal and choroidal endothelial cells. Exp Eye Res. 2014;121:161–7. https://doi.org/10.1016/j.exer.2014.02.016.
Rangasamy S, Srinivasan R, Maestas J, et al. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Investig Opthalmology Vis Sci. 2011;52:3784. https://doi.org/10.1167/iovs.10-6386.
Hofman P, Blaauwgeers HG, Tolentino MJ, et al. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A. Curr Eye Res. 2000;21:637–45.
Feng Y, Venema VJ, Venema RC, et al. VEGF-induced permeability increase is mediated by caveolae. Invest Ophthalmol Vis Sci. 1999;40:157–67.
Wisniewska-Kruk J, Van Der Wijk A-E, Van Veen HA, et al. Plasmalemma vesicle-associated protein has a key role in blood-retinal barrier loss. Am J Pathol. 2016;186:1044–54. https://doi.org/10.1016/j.ajpath.2015.11.019.
Joussen AM, Doehmen S, Le ML, et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis. 2009;15:1418–28.
Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest. 1996;97:2883–90. https://doi.org/10.1172/JCI118746.
Al-Shabrawey M, Ahmad S, Megyerdi S, et al. Caspase-14: a novel caspase in the retina with a potential role in diabetic retinopathy. Mol Vis. 2012;18:1895–906.
Lin J, Chen M, Liu D, et al. Exogenous hydrogen sulfide protects human umbilical vein endothelial cells against high glucose-induced injury by inhibiting the necroptosis pathway. Int J Mol Med. 2018;41:1477–86. https://doi.org/10.3892/ijmm.2017.3330.
Zhang J, Qiu Q, Wang H, et al. TRIM46 contributes to high glucose-induced ferroptosis and cell growth inhibition in human retinal capillary endothelial cells by facilitating GPX4 ubiquitination. Exp Cell Res. 2021;407: 112800. https://doi.org/10.1016/j.yexcr.2021.112800.
Liu Y, Zhang Z, Yang J, et al. lncRNA ZFAS1 positively facilitates endothelial ferroptosis via miR-7-5p/ACSL4 axis in diabetic retinopathy. Oxid Med Cell Longev. 2022;2022:1–17. https://doi.org/10.1155/2022/9004738.
Chen W, Zhao M, Zhao S, et al. Activation of the TXNIP/NLRP3 inflammasome pathway contributes to inflammation in diabetic retinopathy: a novel inhibitory effect of minocycline. Inflamm Res. 2017;66:157–66. https://doi.org/10.1007/s00011-016-1002-6.
Gu C, Draga D, Zhou C, et al. miR-590-3p inhibits pyroptosis in diabetic retinopathy by targeting NLRP1 and inactivating the NOX4 signaling pathway. Investig Opthalmology Vis Sci. 2019;60:4215. https://doi.org/10.1167/iovs.19-27825.
Wang Q, Zhao T, Zhang W, et al. Poly (ADP-ribose) polymerase 1 mediated arginase II activation is responsible for oxidized LDL-induced endothelial dysfunction. Front Pharmacol. 2018;9:882. https://doi.org/10.3389/fphar.2018.00882.
Oshitari T. Neurovascular cell death and therapeutic strategies for diabetic retinopathy. Int J Mol Sci. 2023;24:12919. https://doi.org/10.3390/ijms241612919.
Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002;160:501–9. https://doi.org/10.1016/S0002-9440(10)64869-9.
Mondragon AA, Betts-Obregon BS, Moritz RJ, et al. BIGH3 protein and macrophages in retinal endothelial cell apoptosis. Apoptosis. 2015;20:29–37. https://doi.org/10.1007/s10495-014-1052-6.
Xie H, Zhang C, Liu D, et al. Erythropoietin protects the inner blood–retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy. Diabetologia. 2021;64:211–25. https://doi.org/10.1007/s00125-020-05299-x.
Huang H. Pericyte-endothelial interactions in the retinal microvasculature. Int J Mol Sci. 2020;21:7413. https://doi.org/10.3390/ijms21197413.
Darland DC, Massingham LJ, Smith SR, et al. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol. 2003;264:275–88. https://doi.org/10.1016/j.ydbio.2003.08.015.
Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 1998;125:1591–8. https://doi.org/10.1242/dev.125.9.1591.
Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005;97:512–23. https://doi.org/10.1161/01.RES.0000182903.16652.d7.
Zheng Z, Chopp M, Chen J. Multifaceted roles of pericytes in central nervous system homeostasis and disease. J Cereb Blood Flow Metab. 2020;40:1381–401. https://doi.org/10.1177/0271678X20911331.
Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: key functions and signaling pathways. Nat Neurosci. 2016;19:771–83. https://doi.org/10.1038/nn.4288.
Hori S, Ohtsuki S, Hosoya K, et al. A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. J Neurochem. 2004;89:503–13. https://doi.org/10.1111/j.1471-4159.2004.02343.x.
Jiang Q, Liu C, Li C-P, et al. Circular RNA-ZNF532 regulates diabetes-induced retinal pericyte degeneration and vascular dysfunction. J Clin Invest. 2020;130:3833–47. https://doi.org/10.1172/JCI123353.
Liu C, Ge H-M, Liu B-H, et al. Targeting pericyte–endothelial cell crosstalk by circular RNA-cPWWP2A inhibition aggravates diabetes-induced microvascular dysfunction. Proc Natl Acad Sci. 2019;116:7455–64. https://doi.org/10.1073/pnas.1814874116.
Oku H, Kodama T, Sakagami K, Puro DG. Diabetes-induced disruption of gap junction pathways within the retinal microvasculature. Invest Ophthalmol Vis Sci. 2001;42:1915–20.
Larson DM, Carson MP, Haudenschild CC. Junctional transfer of small molecules in cultured bovine brain microvascular endothelial cells and pericytes. Microvasc Res. 1987;34:184–99. https://doi.org/10.1016/0026-2862(87)90052-5.
Fernandes R, Girão H, Pereira P. High glucose down-regulates intercellular communication in retinal endothelial cells by enhancing degradation of connexin 43 by a proteasome-dependent mechanism. J Biol Chem. 2004;279:27219–24. https://doi.org/10.1074/jbc.M400446200.
Li A-F, Roy S. High glucose-induced downregulation of connexin 43 expression promotes apoptosis in microvascular endothelial cells. Investig Opthalmology Vis Sci. 2009;50:1400. https://doi.org/10.1167/iovs.07-1519.
Muto T, Tien T, Kim D, et al. High glucose alters Cx43 expression and gap junction intercellular communication in retinal müller cells: promotes müller cell and pericyte apoptosis. Investig Opthalmology Vis Sci. 2014;55:4327. https://doi.org/10.1167/iovs.14-14606.
Warmke N, Griffin KJ, Cubbon RM. Pericytes in diabetes-associated vascular disease. J Diabet Complicat. 2016;30:1643–50. https://doi.org/10.1016/j.jdiacomp.2016.08.005.
Robison WG, Kador PF, Kinoshita JH. Early retinal microangiopathy: prevention with aldose reductase inhibitors. Diabet Med. 1985;2:196–9. https://doi.org/10.1111/j.1464-5491.1985.tb00635.x.
Hughes S, Gardiner T, Hu P, et al. Altered pericyte–endothelial relations in the rat retina during aging: implications for vessel stability. Neurobiol Aging. 2006;27:1838–47. https://doi.org/10.1016/j.neurobiolaging.2005.10.021.
Figueiredo AM, Villacampa P, Diéguez-Hurtado R, et al. Phosphoinositide 3-kinase–regulated pericyte maturation governs vascular remodeling. Circulation. 2020;142:688–704. https://doi.org/10.1161/CIRCULATIONAHA.119.042354.
Ogura S, Kurata K, Hattori Y, et al. Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown. JCI Insight. 2017. https://doi.org/10.1172/jci.insight.90905.
Rajendran S, Seetharaman S, Dharmarajan A, Kuppan K. Microvascular cells: a special focus on heterogeneity of pericytes in diabetes associated complications. Int J Biochem Cell Biol. 2021;134: 105971. https://doi.org/10.1016/j.biocel.2021.105971.
Kowluru RA. Diabetic retinopathy: mitochondrial dysfunction and retinal capillary cell death. Antioxid Redox Signal. 2005;7:1581. https://doi.org/10.1089/ars.2005.7.1581.
Beltramo E, Porta M. Pericyte loss in diabetic retinopathy: mechanisms and consequences. Curr Med Chem. 2013;20:3218–25. https://doi.org/10.2174/09298673113209990022.
Chen B, Jiang D, Tang L. Advanced glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes. Life Sci. 2006;79:1040–8. https://doi.org/10.1016/j.lfs.2006.03.020.
Zhang S-S, Hu J-Q, Liu X-H, et al. Role of moesin phosphorylation in retinal pericyte migration and detachment induced by advanced glycation endproducts. Front Endocrinol. 2020;11: 603450. https://doi.org/10.3389/fendo.2020.603450.
Ejaz S, Chekarova I, Ejaz A, et al. Importance of pericytes and mechanisms of pericyte loss during diabetic retinopathy. Diabet Obes Metab. 2008;10:53–63. https://doi.org/10.1111/j.1463-1326.2007.00795.x.
Joussen AM, Ricci F, Paris LP, et al. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021;35:1305–16. https://doi.org/10.1038/s41433-020-01377-x.
Park SW, Yun J-H, Kim JH, et al. Angiopoietin 2 induces pericyte apoptosis via α3β1 integrin signaling in diabetic retinopathy. Diabetes. 2014;63:3057–68. https://doi.org/10.2337/db13-1942.
Cao R, Xue Y, Hedlund E-M, et al. VEGFR1–mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy. Proc Natl Acad Sci. 2010;107:856–61. https://doi.org/10.1073/pnas.0911661107.
Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008;456:809–13. https://doi.org/10.1038/nature07424.
Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKC-δ and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med. 2009;15:1298–306. https://doi.org/10.1038/nm.2052.
Kim YH, Kim YS, Park SY, et al. CaMKII regulates pericyte loss in the retina of early diabetic mouse. Mol Cell. 2011;31:289–93. https://doi.org/10.1007/s10059-011-0038-2.
Betts-Obregon BS, Mondragon AA, Mendiola AS, et al. TGFβ induces BIGH3 expression and human retinal pericyte apoptosis: a novel pathway of diabetic retinopathy. Eye. 2016;30:1639–47. https://doi.org/10.1038/eye.2016.179.
Yang R, Liu H, Williams I, Chaqour B. Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy. Ann N Y Acad Sci. 2007;1103:196–201. https://doi.org/10.1196/annals.1394.000.
Sene A, Tadayoni R, Pannicke T, et al. Functional implication of Dp71 in osmoregulation and vascular permeability of the retina. PLoS ONE. 2009;4: e7329. https://doi.org/10.1371/journal.pone.0007329.
Verkman AS, Ruiz-Ederra J, Levin MH. Functions of aquaporins in the eye. Prog Retin Eye Res. 2008;27:420–33. https://doi.org/10.1016/j.preteyeres.2008.04.001.
Tretiach M, Madigan MC, Wen L, Gillies MC. Effect of müller cell co-culture on in vitro permeability of bovine retinal vascular endothelium in normoxic and hypoxic conditions. Neurosci Lett. 2005;378:160–5. https://doi.org/10.1016/j.neulet.2004.12.026.
Barber AJ, Antonetti DA, Gardner TW. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The penn state retina research group. Invest Ophthalmol Vis Sci. 2000;41:3561–8.
Shen W, Li S, Chung SH, Gillies MC. Retinal vascular changes after glial disruption in rats. J Neurosci Res. 2010;88:1485–99. https://doi.org/10.1002/jnr.22317.
Byrne LC, Khalid F, Lee T, et al. AAV-mediated, optogenetic ablation of müller glia leads to structural and functional changes in the mouse retina. PLoS ONE. 2013;8: e76075. https://doi.org/10.1371/journal.pone.0076075.
Portillo J-AC, Lopez Corcino Y, Miao Y, et al. CD40 in retinal müller cells induces P2X7-dependent cytokine expression in macrophages/microglia in diabetic mice and development of early experimental diabetic retinopathy. Diabetes. 2017;66:483–93. https://doi.org/10.2337/db16-0051.
Portillo J-AC, Lopez Corcino Y, Dubyak GR, et al. Ligation of CD40 in human müller cells induces P2X 7 receptor-dependent death of retinal endothelial cells. Investig Opthalmology Vis Sci. 2016;57:6278. https://doi.org/10.1167/iovs.16-20301.
Subauste CS. The CD40-ATP-P2X7 receptor pathway: cell to cell cross-talk to promote inflammation and programmed cell death of endothelial cells. Front Immunol. 2019;10:2958. https://doi.org/10.3389/fimmu.2019.02958.
Schnitzer J. Astrocytes in the guinea pig, horse, and monkey retina: Their occurrence coincides with the presence of blood vessels. Glia. 1988;1:74–89. https://doi.org/10.1002/glia.440010109.
Schnitzer J. Retinal astrocytes: their restriction to vascularized parts of the mammalian retina. Neurosci Lett. 1987;78:29–34. https://doi.org/10.1016/0304-3940(87)90556-8.
Zhang Y, Stone J. Role of astrocytes in the control of developing retinal vessels. Invest Ophthalmol Vis Sci. 1997;38:1653–66.
Kaur C, Foulds W, Ling E. Blood–retinal barrier in hypoxic ischaemic conditions: Basic concepts, clinical features and management. Prog Retin Eye Res. 2008;27:622–47. https://doi.org/10.1016/j.preteyeres.2008.09.003.
Rungger-Brändle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2000;41:1971–80.
Gardner TW, Lieth E, Khin SA, et al. Astrocytes increase barrier properties and ZO-1 expression in retinal vascular endothelial cells. Invest Ophthalmol Vis Sci. 1997;38:2423–7.
Fresta CG, Fidilio A, Caruso G, et al. A new human blood-retinal barrier model based on endothelial cells, pericytes, and astrocytes. Int J Mol Sci. 2020;21:1636. https://doi.org/10.3390/ijms21051636.
Wisniewska-Kruk J, Hoeben KA, Vogels IMC, et al. A novel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytes. Exp Eye Res. 2012;96:181–90. https://doi.org/10.1016/j.exer.2011.12.003.
Rübsam A, Parikh S, Fort P. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19:942. https://doi.org/10.3390/ijms19040942.
Yun J-H, Park SW, Kim JH, et al. Angiopoietin 2 induces astrocyte apoptosis via αvβ5-integrin signaling in diabetic retinopathy. Cell Death Dis. 2016;7:e2101–e2101. https://doi.org/10.1038/cddis.2015.347.
Mills SA, Jobling AI, Dixon MA, et al. Fractalkine-induced microglial vasoregulation occurs within the retina and is altered early in diabetic retinopathy. Proc Natl Acad Sci. 2021;118: e2112561118. https://doi.org/10.1073/pnas.2112561118.
Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54:1559–65. https://doi.org/10.2337/diabetes.54.5.1559.
Jiang M, Xie H, Zhang C, et al. Enhancing fractalkine/CX3CR1 signalling pathway can reduce neuroinflammation by attenuating microglia activation in experimental diabetic retinopathy. J Cell Mol Med. 2022;26:1229–44. https://doi.org/10.1111/jcmm.17179.
Takeda A, Shinozaki Y, Kashiwagi K, et al. Microglia mediate non-cell-autonomous cell death of retinal ganglion cells. Glia. 2018;66:2366–84. https://doi.org/10.1002/glia.23475.
Yun J, Park SW, Kim K, et al. Endothelial STAT3 activation increases vascular leakage through downregulating tight junction proteins: implications for diabetic retinopathy. J Cell Physiol. 2017;232:1123–34. https://doi.org/10.1002/jcp.25575.
Tang L, Zhang C, Lu L, et al. Melatonin maintains inner blood-retinal barrier by regulating microglia via inhibition of PI3K/Akt/Stat3/NF-κB signaling pathways in experimental diabetic retinopathy. Front Immunol. 2022;13: 831660. https://doi.org/10.3389/fimmu.2022.831660.
Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015;49:67–81. https://doi.org/10.1016/j.preteyeres.2015.06.002.
Campochiaro PA, Akhlaq A. Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases. Prog Retin Eye Res. 2021;83: 100921. https://doi.org/10.1016/j.preteyeres.2020.100921.
Roy H, Bhardwaj S, Ylä-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett. 2006;580:2879–87. https://doi.org/10.1016/j.febslet.2006.03.087.
Van Bergen T, Etienne I, Cunningham F, et al. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. Prog Retin Eye Res. 2019;69:116–36. https://doi.org/10.1016/j.preteyeres.2018.10.006.
Uemura A, Fruttiger M, D’Amore PA, et al. VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res. 2021;84: 100954. https://doi.org/10.1016/j.preteyeres.2021.100954.
Okabe K, Kobayashi S, Yamada T, et al. Neurons limit angiogenesis by titrating VEGF in retina. Cell. 2014;159:584–96. https://doi.org/10.1016/j.cell.2014.09.025.
Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176:1248–64. https://doi.org/10.1016/j.cell.2019.01.021.
Mäkinen T, Veikkola T, Mustjoki S, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 2001;20:4762–73. https://doi.org/10.1093/emboj/20.17.4762.
Leppänen V-M, Tvorogov D, Kisko K, et al. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proc Natl Acad Sci. 2013;110:12960–5. https://doi.org/10.1073/pnas.1301415110.
Kurihara T, Westenskow PD, Friedlander M, et al. Hypoxia-inducible factor (HIF)/vascular endothelial growth factor (VEGF) signaling in the retina. In: Ash JD, Grimm C, Hollyfield JG, et al., editors. Retinal degenerative diseases. New York: Springer; 2014. p. 275–81.
Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27:331–71. https://doi.org/10.1016/j.preteyeres.2008.05.001.
Behzadian MA, Windsor LJ, Ghaly N, et al. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J. 2003;17:752–4. https://doi.org/10.1096/fj.02-0484fje.
Witmer A. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1–29. https://doi.org/10.1016/S1350-9462(02)00043-5.
Murakami T, Frey T, Lin C, Antonetti DA. Protein kinase cβ phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo. Diabetes. 2012;61:1573–83. https://doi.org/10.2337/db11-1367.
Harhaj NS, Felinski EA, Wolpert EB, et al. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci. 2006;47:5106–15. https://doi.org/10.1167/iovs.06-0322.
Scheppke L, Aguilar E, Gariano RF, et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest. 2008;118:2337–46. https://doi.org/10.1172/JCI33361.
Lee Y-J, Jung S-H, Kim S-H, et al. Essential role of transglutaminase 2 in vascular endothelial growth factor-induced vascular leakage in the retina of diabetic mice. Diabetes. 2016;65:2414–28. https://doi.org/10.2337/db15-1594.
Klaassen I, Hughes JM, Vogels IMC, et al. Altered expression of genes related to blood–retina barrier disruption in streptozotocin-induced diabetes. Exp Eye Res. 2009;89:4–15. https://doi.org/10.1016/j.exer.2009.01.006.
Miyamoto K, Khosrof S, Bursell S-E, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol. 2000;156:1733–9. https://doi.org/10.1016/S0002-9440(10)65044-4.
Olofsson B, Pajusola K, Von Euler G, et al. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem. 1996;271:19310–7. https://doi.org/10.1074/jbc.271.32.19310.
Grimmond S, Lagercrantz J, Drinkwater C, et al. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res. 1996;6:124–31. https://doi.org/10.1101/gr.6.2.124.
Yoon Y, Losordo DW. All in the family: VEGF-B joins the ranks of proangiogenic cytokines. Circ Res. 2003;93:87–90. https://doi.org/10.1161/01.RES.0000084992.10766.36.
Silvestre J-S, Tamarat R, Ebrahimian TG, et al. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res. 2003;93:114–23. https://doi.org/10.1161/01.RES.0000081594.21764.44.
Mould AW, Greco SA, Cahill MM, et al. Transgenic overexpression of vascular endothelial growth factor-b isoforms by endothelial cells potentiates postnatal vessel growth in vivo and in vitro. Circ Res. 2005. https://doi.org/10.1161/01.RES.0000182631.33638.77.
Aase K, Von Euler G, Li X, et al. Vascular endothelial growth factor-b–deficient mice display an atrial conduction defect. Circulation. 2001;104:358–64. https://doi.org/10.1161/01.CIR.104.3.358.
Reichelt M, Shi S, Hayes M, et al. Vascular endothelial growth factor-B and retinal vascular development in the mouse. Clin Exp Ophthalmol. 2003;31:61–5. https://doi.org/10.1046/j.1442-9071.2003.00602.x.
Malik AK, Baldwin ME, Peale F, et al. Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. Blood. 2006;107:550–7. https://doi.org/10.1182/blood-2005-05-2047.
Zhong X, Huang H, Shen J, et al. Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation. Mol Vis. 2011;17:492–507.
Zhang F, Tang Z, Hou X, et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci. 2009;106:6152–7. https://doi.org/10.1073/pnas.0813061106.
Chen R, Lee C, Lin X, et al. Novel function of VEGF-B as an antioxidant and therapeutic implications. Pharmacol Res. 2019;143:33–9. https://doi.org/10.1016/j.phrs.2019.03.002.
Kinoshita S, Noda K, Saito W, et al. Vitreous levels of vascular endothelial growth factor-B in proliferative diabetic retinopathy. Acta Ophthalmol. 2016. https://doi.org/10.1111/aos.12969.
Mesquita J, Castro De Sousa J, Vaz-Pereira S, et al. VEGF-B levels in the vitreous of diabetic and non-diabetic patients with ocular diseases and its correlation with structural parameters. Med Sci. 2017;5:17. https://doi.org/10.3390/medsci5030017.
Mesquita J, Castro-de-Sousa JP, Vaz-Pereira S, et al. Evaluation of the growth factors VEGF-a and VEGF-B in the vitreous and serum of patients with macular and retinal vascular diseases. Growth Fact. 2018;36:48–57. https://doi.org/10.1080/08977194.2018.1477140.
Kovacs K, Marra KV, Yu G, et al. Angiogenic and inflammatory vitreous biomarkers associated with increasing levels of retinal ischemia. Investig Opthalmology Vis Sci. 2015;56:6523. https://doi.org/10.1167/iovs.15-16793.
Ando R, Noda K, Namba S, et al. Aqueous humour levels of placental growth factor in diabetic retinopathy. Acta Ophthalmol. 2014. https://doi.org/10.1111/aos.12251.
Van Bergen T, Hu T-T, Etienne I, et al. Neutralization of placental growth factor as a novel treatment option in diabetic retinopathy. Exp Eye Res. 2017;165:136–50. https://doi.org/10.1016/j.exer.2017.09.012.
Huang H, He J, Johnson D, et al. Deletion of placental growth factor prevents diabetic retinopathy and is associated with akt activation and HIF1α-VEGF pathway inhibition. Diabetes. 2015;64:200–12. https://doi.org/10.2337/db14-0016.
He J, Wang H, Liu Y, et al. Blockade of vascular endothelial growth factor receptor 1 prevents inflammation and vascular leakage in diabetic retinopathy. J Ophthalmol. 2015;2015:1–11. https://doi.org/10.1155/2015/605946.
Li S, Tao Y, Yang M, et al. Aflibercept 5+PRN with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+PRN with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular edema: a 12-month clinical trial. Front Endocrinol. 2024;15:1286736. https://doi.org/10.3389/fendo.2024.1286736.
Augustin HG, Young Koh G, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin–tie system. Nat Rev Mol Cell Biol. 2009;10:165–77. https://doi.org/10.1038/nrm2639.
Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin-tie pathway. Nat Rev Drug Discov. 2017;16:635–61. https://doi.org/10.1038/nrd.2016.278.
Teichert M, Milde L, Holm A, et al. Pericyte-expressed Tie2 controls angiogenesis and vessel maturation. Nat Commun. 2017;8:16106. https://doi.org/10.1038/ncomms16106.
Korhonen EA, Lampinen A, Giri H, et al. Tie1 controls angiopoietin function in vascular remodeling and inflammation. J Clin Invest. 2016;126:3495–510. https://doi.org/10.1172/JCI84923.
Hakanpaa L, Sipila T, Leppanen V-M, et al. Endothelial destabilization by angiopoietin-2 via integrin β1 activation. Nat Commun. 2015;6:5962. https://doi.org/10.1038/ncomms6962.
Felcht M, Luck R, Schering A, et al. Angiopoietin-2 differentially regulates angiogenesis through Tie2 and integrin signaling. J Clin Invest. 2012;122:1991–2005. https://doi.org/10.1172/JCI58832.
Vestweber D. Vascular endothelial protein tyrosine phosphatase regulates endothelial function. Physiology. 2021;36:84–93. https://doi.org/10.1152/physiol.00026.2020.
Uemura A, Ogawa M, Hirashima M, et al. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest. 2002;110:1619–28. https://doi.org/10.1172/JCI0215621.
Cai J, Kehoe O, Smith GM, et al. The angiopoietin/tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. Investig Opthalmology Vis Sci. 2008;49:2163. https://doi.org/10.1167/iovs.07-1206.
Pfister F, Feng Y, vom Hagen F, et al. Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes. 2008;57:2495–502. https://doi.org/10.2337/db08-0325.
Thomas M, Felcht M, Kruse K, et al. Angiopoietin-2 stimulation of endothelial cells induces αvβ3 integrin internalization and degradation. J Biol Chem. 2010;285:23842–9. https://doi.org/10.1074/jbc.M109.097543.
Hammes H-P, Lin J, Wagner P, et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes. 2004;53:1104–10. https://doi.org/10.2337/diabetes.53.4.1104.
Agard NJ, Zhang G, Ridgeway J, et al. Direct Tie2 agonists stabilize vasculature for the treatment of diabetic macular edema. Transl Vis Sci Technol. 2022;11:27. https://doi.org/10.1167/tvst.11.10.27.
Regula JT, Lundh Von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific Cross ma b optimized for neovascular eye diseases. EMBO Mol Med. 2016;8:1265–88. https://doi.org/10.15252/emmm.201505889.
Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2005;139:476–81. https://doi.org/10.1016/j.ajo.2004.10.004.
Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. The Lancet. 2022;399:741–55. https://doi.org/10.1016/S0140-6736(22)00018-6.
Braun LJ, Zinnhardt M, Vockel M, et al. VE—PTP inhibition stabilizes endothelial junctions by activating FGD 5. EMBO Rep. 2019. https://doi.org/10.1525/embr.201847046.
Shen J, Frye M, Lee BL, et al. Targeting VE-PTP activates Tie2 and stabilizes the ocular vasculature. J Clin Invest. 2014;124:4564–76. https://doi.org/10.1172/JCI74527.
Campochiaro PA, Sophie R, Tolentino M, et al. Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology. 2015;122:545–54. https://doi.org/10.1016/j.ophtha.2014.09.023.
Campochiaro PA, Khanani A, Singer M, et al. Enhanced benefit in diabetic macular edema from AKB-9778 Tie2 activation combined with vascular endothelial growth factor suppression. Ophthalmology. 2016;123:1722–30. https://doi.org/10.1016/j.ophtha.2016.04.025.
Abramsson A, Kurup S, Busse M, et al. Defective N -sulfation of heparan sulfate proteoglycans limits PDGF-BB binding and pericyte recruitment in vascular development. Genes Dev. 2007;21:316–31. https://doi.org/10.1101/gad.398207.
Gaengel K, Genové G, Armulik A, Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol. 2009;29:630–8. https://doi.org/10.1161/ATVBAHA.107.161521.
Lindblom P, Gerhardt H, Liebner S, et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 2003;17:1835–40. https://doi.org/10.1101/gad.266803.
Weiss A, Attisano L. The TGFbeta superfamily signaling pathway. WIREs Dev Biol. 2013;2:47–63. https://doi.org/10.1002/wdev.86.
Schmierer B, Hill CS. TGFβ–SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 2007;8:970–82. https://doi.org/10.1038/nrm2297.
Santibañez JF, Quintanilla M, Bernabeu C. TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. Clin Sci. 2011;121:233–51. https://doi.org/10.1042/CS20110086.
Derynck R, Zhang YE. Smad-dependent and smad-independent pathways in TGF-β family signalling. Nature. 2003;425:577–84. https://doi.org/10.1038/nature02006.
Zhang YE. Non-smad signaling pathways of the TGF-β family. Cold Spring Harb Perspect Biol. 2017;9: a022129. https://doi.org/10.1101/cshperspect.a022129.
Dai Y, Wu Z, Wang F, et al. Identification of chemokines and growth factors in proliferative diabetic retinopathy vitreous. BioMed Res Int. 2014;2014:1–9. https://doi.org/10.1155/2014/486386.
Hirase K. Transforming growth factor β2 in the vitreous in proliferative diabetic retinopathy. Arch Ophthalmol. 1998;116:738. https://doi.org/10.1001/archopht.116.6.738.
Behzadian MA, Wang XL, Windsor LJ, et al. TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function. Invest Ophthalmol Vis Sci. 2001;42:853–9.
Behzadian MA, Wang XL, Al-Shabrawey M, Caldwell RB. Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-beta. Glia. 1998;24:216–25.
Li F, Lan Y, Wang Y, et al. Endothelial smad4 maintains cerebrovascular integrity by activating N-cadherin through cooperation with notch. Dev Cell. 2011;20:291–302. https://doi.org/10.1016/j.devcel.2011.01.011.
Elmasry K, Habib S, Moustafa M, Al-Shabrawey M. Bone morphogenetic proteins and diabetic retinopathy. Biomolecules. 2021;11:593. https://doi.org/10.3390/biom11040593.
Darwish NHE, Hussein KA, Elmasry K, et al. Bone morphogenetic protein-4 impairs retinal endothelial cell barrier, a potential role in diabetic retinopathy. Cells. 2023;12:1279. https://doi.org/10.3390/cells12091279.
Hussein KA, Choksi K, Akeel S, et al. Bone morphogenetic protein 2: a potential new player in the pathogenesis of diabetic retinopathy. Exp Eye Res. 2014;125:79–88. https://doi.org/10.1016/j.exer.2014.05.012.
Bouletreau PJ, Warren SM, Spector JA, et al. Hypoxia and VEGF up-regulate BMP-2 mRNA and protein expression in microvascular endothelial cells: implications for fracture healing. Plast Reconstr Surg. 2002;109:2384–97. https://doi.org/10.1097/00006534-200206000-00033.
Al-Shabrawey M, Hussein K, Wang F, et al. Bone morphogenetic protein-2 induces non-canonical inflammatory and oxidative pathways in human retinal endothelial cells. Front Immunol. 2021;11: 568795. https://doi.org/10.3389/fimmu.2020.568795.
Lei D, Jin X, Wen L, et al. bmp3 is required for integrity of blood brain barrier by promoting pericyte coverage in zebrafish embryos. Curr Mol Med. 2017. https://doi.org/10.2174/1566524017666171106114234.
Dong L, Zhang Z, Liu X, et al. RNA sequencing reveals BMP4 as a basis for the dual-target treatment of diabetic retinopathy. J Mol Med. 2021;99:225–40. https://doi.org/10.1007/s00109-020-01995-8.
Liu M, Li Z, Zhang H, et al. Inhibition of BMP4 alleviates diabetic retinal vascular dysfunction via the VEGF and smad1/5 signalling. Arch Physiol Biochem. 2023. https://doi.org/10.1080/13813455.2023.2190054.
Akla N, Viallard C, Popovic N, et al. BMP9 (bone morphogenetic protein-9)/Alk1 (activin-like kinase receptor type I) signaling prevents hyperglycemia-induced vascular permeability. Arterioscler Thromb Vasc Biol. 2018;38:1821–36. https://doi.org/10.1161/ATVBAHA.118.310733.
Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010;106:1319–31. https://doi.org/10.1161/CIRCRESAHA.110.217117.
Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science. 1996;272:728–31. https://doi.org/10.1126/science.272.5262.728.
The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy. Diabetes. 2005;54:2188–97. https://doi.org/10.2337/diabetes.54.7.2188.
Worzfeld T, Offermanns S. Semaphorins and plexins as therapeutic targets. Nat Rev Drug Discov. 2014;13:603–21. https://doi.org/10.1038/nrd4337.
Roth L, Koncina E, Satkauskas S, et al. The many faces of semaphorins: from development to pathology. Cell Mol Life Sci. 2009;66:649. https://doi.org/10.1007/s00018-008-8518-z.
Li Y, Liang H, Zhang C, et al. Ophthalmic solution of smart supramolecular peptides to capture semaphorin 4D against diabetic retinopathy. Adv Sci. 2023;10:2203351. https://doi.org/10.1002/advs.202203351.
Wu J, Li Y, Chen A, et al. Inhibition of Sema4D/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy. EMBO Mol Med. 2020. https://doi.org/10.15252/emmm.201810154.
Rosen H, Stevens RC, Hanson M, et al. Sphingosine-1-phosphate and its receptors: structure, signaling, and influence. Annu Rev Biochem. 2013;82:637–62. https://doi.org/10.1146/annurev-biochem-062411-130916.
Gaengel K, Niaudet C, Hagikura K, et al. The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2. Dev Cell. 2012;23:587–99. https://doi.org/10.1016/j.devcel.2012.08.005.
Jung B, Obinata H, Galvani S, et al. Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development. Dev Cell. 2012;23:600–10. https://doi.org/10.1016/j.devcel.2012.07.015.
Alshaikh RA, Ryan KB, Waeber C. Sphingosine 1-phosphate, a potential target in neovascular retinal disease. Br J Ophthalmol. 2022;106:1187–95. https://doi.org/10.1136/bjophthalmol-2021-319115.
Wan Y, Jin H-J, Zhu Y-Y, et al. MicroRNA-149–5p regulates blood–brain barrier permeability after transient middle cerebral artery occlusion in rats by targeting S1PR2 of pericytes. FASEB J. 2018;32:3133–48. https://doi.org/10.1096/fj.201701121R.
Ensari Delioğlu E, Uğurlu N, Erdal E, et al. Evaluation of sphingolipid metabolism on diabetic retinopathy. Indian J Ophthalmol. 2021;69:3376. https://doi.org/10.4103/ijo.IJO_3724_20.
Niaudet C, Jung B, Kuo A, et al. Therapeutic activation of endothelial sphingosine-1-phosphate receptor 1 by chaperone-bound S1P suppresses proliferative retinal neovascularization. EMBO Mol Med. 2023. https://doi.org/10.15252/emmm.202216645.
Kaczmarek R, Gajdzis P, Gajdzis M. Eph receptors and ephrins in retinal diseases. Int J Mol Sci. 2021;22:6207. https://doi.org/10.3390/ijms22126207.
Foo SS, Turner CJ, Adams S, et al. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell. 2006;124:161–73. https://doi.org/10.1016/j.cell.2005.10.034.
Li Y, Chen D, Sun L, et al. Induced expression of VEGFC, ANGPT, and EFNB2 and their receptors characterizes neovascularization in proliferative diabetic retinopathy. Investig Opthalmology Vis Sci. 2019;60:4084. https://doi.org/10.1167/iovs.19-26767.
Yuuki T, Kanda T, Kishi S. Expression of ephrin in retinal neovascularization and iris rubeosis. J Int Med Res. 2006;34:485–94. https://doi.org/10.1177/147323000603400505.
Pitulescu ME, Adams RH. Regulation of signaling interactions and receptor endocytosis in growing blood vessels. Cell Adhes Migr. 2014;8:366–77. https://doi.org/10.4161/19336918.2014.970010.
Coucha M, Barrett AC, Bailey J, et al. Increased Ephrin-B2 expression in pericytes contributes to retinal vascular death in rodents. Vascul Pharmacol. 2020;131: 106761. https://doi.org/10.1016/j.vph.2020.106761.
Nakayama A, Nakayama M, Turner CJ, et al. Ephrin-B2 controls PDGFRβ internalization and signaling. Genes Dev. 2013;27:2576–89. https://doi.org/10.1101/gad.224089.113.
Nishishita T, Lin PC. Angiopoietin 1, PDGF-B, and TGF-β gene regulation in endothelial cell and smooth muscle cell interaction. J Cell Biochem. 2004;91:584–93. https://doi.org/10.1002/jcb.10718.
Antonetti DA, Silva PS, Stitt AW. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat Rev Endocrinol. 2021;17:195–206. https://doi.org/10.1038/s41574-020-00451-4.
Add Comment